Objective: This review aims to provide an overview of pharmacologic management for
hypoactive sexual desire disorder (HSDD) in premenopausal women, with a focus on …

The objective of the authors is to highlight the historical complexities for the diagnosis and
treatment of hypoactive sexual desire disorder (HSDD) with a focus on Flibanserin. A …

Background: Hypoactive sexual desire disorder (HSDD) in premenopausal women involves
biological, psychological, and social aspects. In the European Society for Sexual Medicine …

The objective of the International Society for the Study of Women's Sexual Health expert
consensus panel was to develop a concise, clinically relevant, evidence-based review of the …

Objective: To review data regarding flibanserin, a recently approved therapy for hypoactive
sexual desire disorder (HSDD). Data Sources: Literature search of MEDLINE (September …

ABSTRACT Introduction Hypoactive Sexual Desire Disorder (HSDD) is the most common
form of Female Sexual Dysfunction and is characterized by low sexual desire that causes …

ABSTRACT Introduction Hypoactive Sexual Desire Disorder (HSDD) is characterized by low
sexual desire that causes marked distress or interpersonal difficulty. Aim To assess the …

Abstract Background: Flibanserin, a 5-hydroxytryptamine 5-HT1A agonist and 5-HT2A
antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire …

Introduction: Hypoactive sexual desire disorder (HSDD) is the most common form of female
sexual dysfunction (FSD). Some theories suggest that HSDD has a neurobiological …

Abstract Introduction Hypoactive Sexual Desire Disorder (HSDD) is defined in the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-TR) …